CN106146497A - 苦参碱肟酯衍生物及其制备方法与应用 - Google Patents
苦参碱肟酯衍生物及其制备方法与应用 Download PDFInfo
- Publication number
- CN106146497A CN106146497A CN201610493154.8A CN201610493154A CN106146497A CN 106146497 A CN106146497 A CN 106146497A CN 201610493154 A CN201610493154 A CN 201610493154A CN 106146497 A CN106146497 A CN 106146497A
- Authority
- CN
- China
- Prior art keywords
- matrine
- lhw
- nmr
- mhz
- oxime
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed systems contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/90—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having two or more relevant hetero rings, condensed among themselves or with a common carbocyclic ring system
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Dentistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Plant Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pest Control & Pesticides (AREA)
- Agronomy & Crop Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
Abstract
本发明公开了一种查尔酮衍生物,包括芳基哌嗪、芳基磺酰基哌嗪类苦参碱衍生物,还公开了该衍生物的制备方法和在药物中的应用。
Description
技术领域
本发明涉及制药技术领域,具体涉及苦参碱肟和一类新的苦参碱衍生物,以及制备方法,以及这些化合物在制备抗肿瘤和杀虫药物中的应用。
背景技术
苦参是豆科植物的干燥根,含有多种化学成分。其中,苦参碱是苦参总碱的代表,为羽扇烷宁(白金雀儿碱)的异构体,属于四环的喹嗪啶类。苦参碱是由豆科植物苦参的干燥根、植株、果实经乙醇等有机溶剂提取制成的;具有广泛的药理作用,如抗肿瘤、抗心律失常、抗炎及抗病毒作用,临床上主要用于慢性病毒性肝炎的治疗,毒副作用小,疗效好。
苦参碱是一种天然植物性农药, 对人畜低毒, 是广谱杀虫剂,具有触杀和胃毒作用,对各种作物上的黏虫、菜青虫、蚜虫、红蜘蛛有明显的防治效果。
肟作为一种重要的有机反应中间体,可以用来制备胺、酰胺、噁唑、吡啶、硝酮、肟酯等化合物,在研发中常被选为有效的活性基团,受到医药和农药行业的广泛关注。肟酯类化合物具有优良的杀虫、杀菌及除草活性,不少品种还具有低毒、低残留等优点。目前该类化合物的分子设计和合成以及生物活性是研究的热点,因其具有广泛的生物活性和多变结构类型而倍受人们的关注。
未见兼具苦参碱的杀虫活性与抗肿瘤活性和苯甲酰氯类药物的杀虫和抗肿瘤活性。
发明内容
本发明要解决的技术问题是提供一种用于制备杀虫和抗肿瘤药物的苦参碱衍生物及其制备方面。
本发明所述苦参碱衍生物,其结构如下:
。
本发明还提供了上述化合物的制备方法,该方法采用如下反应路线:
。
涉及到苦参碱肟LHW-01,具体包括以下技术方案:
(1)LHW-01的制备:
具体制备LHW-01的实验方法:
在反应瓶中依次加入1.24g(5mmol)苦参碱和20mL甲苯,搅拌下加入5mL双(三甲基硅基)氨基钠,于室温下反应 10min,然后加入3mL亚硝酸叔丁酯,在50℃下反应 1.5 h(TLC检测)。冷却至室温,真空抽滤,滤液浓缩后经硅胶柱层析[洗脱剂:V(石油醚):V(乙酸乙酯)=1:1]纯化得到0.89g白色固体 LHW-01。收率 65%, m .p. 148 ~ 153℃; 1H NMR (600MHz, CDCl3) δ: 15.21 (s, 1H), 4.32 (dd, J = 12.8, 4.4 Hz, 1H), 3.98 (dd, J =10.9, 7.8, 5.3 Hz, 1H),3.24 (t, J = 12.8 Hz, 1H), 2.90~ 2.76 (m, 2H), 2.66(dd, J = 15.4, 7.4, 3.9 Hz, 1H), 2.49 (dd, J = 15.2, 10.9, 3.9 Hz, 1H), 2.32~2.20 (m, 1H), 2.07~ 1.95 (m, 2H), 1.90 (dd, J = 8.8, 6.9 Hz, 1H), 1.81 ~ 1.68(m, 4H), 1.66 ~ 1.55 (m, 3H), 1.53 ~ 1.41 (m, 3H), 1.33 ~ 1.21 (m, 1H); 13CNMR(600 MHz, CDCl3)δ: 160.94, 142.68, 63.12, 57.08, 57.04, 53.09, 42.48,41.36, 35.64, 27.57, 26.39, 26.04, 24.76, 20.99, 20.57.MS m/z: 278{ [M+H]+};
(2)LHW-02的制备:
具体制备LHW-02的实验方法:
在反应瓶中依次加入1g LHW-01和 20mL 二氯甲烷,搅拌使其溶解;加入0.5mL吡啶,然后缓慢滴加 10%的苯甲酰氯的二氯甲烷溶液,滴毕,升温回流;TLC 检测,用饱和碳酸氢钠溶液洗 2次,再用水洗 2次,至Ph=7,无水硫酸钠干燥,浓缩,用石油醚和乙酸乙酯混合液进行重结晶,得到LHW-02。淡黄色固体,收率 55%, m.p. 142 ~ 148℃; 1H NMR (600 MHz,CDCl3) δ : 12~8.06 (m, 2H), 7.66 ~ 7.61 (m, 1H), 7.50 (dd, J = 10.8, 4.9 Hz,2H), 4.51 (dd, J = 12.8, 4.5 Hz, 1H), 4.08 (ddd, J = 10.8, 8.0, 5.0 Hz, 1H),3.28 (t, J = 12.8 Hz, 1H), 3.22 (ddd, J = 16.3, 7.3, 4.3 Hz, 1H), 2.92 ~ 2.78(m, 2H), 2.75 ~ 2.63 (m, 1H), 2.29 (ddt, J = 17.2, 7.3, 4.9 Hz, 1H),2.01(dtd, J = 15.0, 12.3, 2.8 Hz, 2H), 1.85 (s, 3H), 1.78 ~ 1.70 (m, 3H), 1.65(ddd, J = 14.3, 9.1, 4.5 Hz, 1H), 1.61 ~ 1.53 (m, 2H), 1.53 ~ 1.46 (m, 3H);13C NMR(600 MHz, CDCl3)δ: 162.89, 158.06, 157.85, 133.64, 129.80, 128.65,128.55, 63.33, 57.12, 56.82, 52.72, 42.89, 42.38, 35.52, 27.56, 26.41, 23.36,22.42, 21.04, 20.72; MS m/z: 382{[M+H]+};
参考化合物LHW-02的实验方法制备化合物LHW-03~LHW-24;
化合物LHW-03~LHW-24结构鉴定数据如下:
化合物LHW-03:白色固体粉末,收率48%,m .p.116~122℃;1H NMR (600 MHz, CDCl3)δ 7.86 (dd, J = 7.8, 1.1 Hz, 1H), 7.45 (td, J = 7.6, 1.3 Hz, 1H),7.32 – 7.24(m, 1H), 4.49 (dd, J = 12.8, 4.5 Hz, 1H), 4.04 (ddd, J = 11.0, 8.1, 5.2 Hz,1H),3.26 (t, J = 12.7 Hz, 1H), 3.14 (ddd, J = 16.4, 7.3, 4.3 Hz, 1H), 2.83(dd, J = 30.3, 11.0 Hz,1H), 2.67 – 2.57 (m, 2H), 2.30 – 2.20 (m, 1H), 1.99(dd, J = 22.3, 10.0 Hz, 2H), 1.86 (d, J =13.8 Hz, 1H), 1.83 – 1.77 (m, 1H),1.77 – 1.65 (m, 2H), 1.65 – 1.60 (m, 1H), 1.60 – 1.51 (m,1H), 1.51 – 1.41 (m,2H);13C NMR(600 MHz, CDCl3)δ: 171.07, 159.77, 148.79, 138.0, 137.89 13.82,130.70,130.44, 130.09, 128.21, 127.27, 63.60, 56.93, 56.80, 54.33, 52.57,42.71, 41.86, 42.71, 41.86,35.54, 27.44, 26.34, 23.02, 21.26, 20.81, 20.46,19.77; MS m/z: 382{[M+H]+};
化合物LHW-04:黄色固体粉末,收率57%,m .p.170~179℃; 1H NMR (600 MHz, CDCl3)δ 7.83 (dd, J = 7.7, 1.8 Hz, 1H), 7.51 (ddd, J =9.0, 7.5, 1.8 Hz, 1H), 7.03 –6.97 (m, 1H), 4.48 (dd, J = 12.8, 4.5 Hz, 1H), 4.08 – 3.98 (m,1H), 3.89 (s,2H), 3.24 (dd, J = 22.2, 9.4 Hz, 1H), 3.19 (ddd, J = 16.3, 7.1, 4.3 Hz, 1H),2.91 –2.76 (m, 1H), 2.65 – 2.54 (m, 1H), 2.24 (ddt, J = 13.7, 7.0, 4.9 Hz,1H), 1.98 (dtd, J = 15.2,12.3, 2.5 Hz, 1H), 1.85 (t, J = 14.4 Hz, 1H), 1.78(ddd, J = 15.5, 8.6, 3.3 Hz, 1H), 1.75 – 1.58(m, 2H), 1.58 – 1.50 (m, 1H),1.50 – 1.41 (m, 2H); 13C NMR δ: 163.18, 159.14, 158.21,157.72, 134.13,132.00, 120.33, 112.08, 63.29, 57.10, 55.99, 52.75, 42.75, 42.39, 35.47,27.56,26.36, 23.45, 22.56, 21.04, 20.69; MS m/z: 412{[M+H]+};
化合物LHW-05:白色固体粉末,收率41%,m .p.156~165℃;1H NMR (600 MHz, CDCl3)δ 8.09 – 8.00 (m, 1H), 7.61 – 7.54 (m, 1H), 7.27 (t, J = 5.6 Hz,1H), 7.16(dt, J = 22.7, 11.4 Hz, 1H), 4.48 (dd, J = 12.8, 4.5 Hz, 1H), 4.09 – 4.00 (m,1H),3.30 – 3.16 (m, 2H), 2.83 (dd, J = 30.8, 10.7 Hz, 2H), 2.71 – 2.60 (m,1H), 2.30 – 2.19 (m,2H), 1.98 (dt, J = 14.7, 7.5 Hz, 2H), 1.87 (d, J = 13.7Hz, 1H), 1.80 (d, J = 9.2 Hz, 1H), 1.77 – 1.66 (m, 3H),1.66 – 1.62 (m, 1H),1.62 – 1.51 (m, 2H), 1.51 – 1.42 (m, 3H); 13C NMR (600 MHz, CDCl3)δ:162.52,160.80, 158.21, 158.00,135.23, 135.17, 132.78, 124.41, 124.39, 117.09,116.94,63.31, 57.12, 52.78, 42.86, 42.37, 35.51, 27.56, 26.39, 23.34, 22.67,21.04, 20.70; MS m/z: 400{[M+H]+};
化合物LHW-06:淡黄色固体粉末,收率52%,m .p.194~203℃;1H NMR (600 MHz, DMSO)δ 7.76 – 7.69 (m, 1H), 7.53 – 7.45 (m, 1H), 7.43 – 7.35 (m, 1H), 4.21 (dd, J= 12.6, 4.4 Hz, 1H), 3.97 – 3.84 (m, 1H), 3.10 (t, J = 12.7 Hz, 1H), 2.85(dd, J =22.5, 11.0 Hz, 1H), 2.73 (ddd, J = 16.5, 8.1, 4.5 Hz, 1H), 2.40 (ddd,J = 16.5, 9.6, 4.7 Hz, 1H), 2.10 – 1.97 (m, 2H), 1.85 (d, J = 13.3 Hz, 1H),1.73 – 1.64 (m, 1H), 1.62 – 1.48 (m, 3H), 1.45 – 1.28 (m, 2H); 13C NMR(600MHz, DMSO) δ: 167.65, 159.75, 149.66, 132.42, 130.97, 130.87, 127.57, 63.35,56.79, 56.74, 52.45, 42.35, 41.35, 35.48, 27.58, 26.20, 23.23, 20.86, 20.42,19.93; MS m/z: 416{[M+H]+};
化合物LHW-07:淡黄色固体粉末,收率45%,m .p.211~215℃;1H NMR (600 MHz, DMSO)δ 7.69 (ddd, J = 7.9, 3.3, 1.4 Hz, 1H), 7.44 (td, J = 7.5, 1.2 Hz,1H), 7.39(td, J = 7.7, 1.8 Hz, 1H), 4.21 (dd, J = 12.6, 4.4 Hz, 1H), 3.94 – 3.84 (m,1H), 3.10(t, J = 12.7 Hz, 1H), 2.84 (dd, J = 22.4, 11.0 Hz, 1H), 2.73 (ddd, J = 16.5, 8.1, 4.5 Hz, 1H),2.51 (dt, J = 3.5, 1.7 Hz, 1H), 2.40 (ddd, J = 16.5,9.6, 4.7 Hz, 1H), 2.10 – 1.97 (m, 2H), 1.83(t, J = 21.9 Hz, 1H), 1.73 – 1.65(m, 1H), 1.63 – 1.48 (m, 3H), 1.45 – 1.31 (m, 2H); 13C NMR(600 MHz, DMSO)δ:168.25, 159.74, 149.67, 134.02, 132.42, 130.79, 128.07, 120.21, 63.36, 56.83,56.77, 52.47, 42.38, 41.38, 35.51, 27.62, 26.24, 23.24, 20.90, 20.45, 19.93;MS m/z: 460{[M+H]+};
化合物LHW-08:淡黄色固体粉末,收率35%,m .p.160~168℃;1H NMR (600 MHz,CDCl3) δ 8.65 (s, 1H), 8.07 (dd, J = 8.6, 1.6 Hz, 1H), 7.98 (d, J = 8.1 Hz,1H), 7.91 (t, J = 8.6 Hz, 2H), 7.66 – 7.60 (m, 1H), 7.60 – 7.54 (m, 1H), 4.51(dd, J = 12.8, 4.5Hz, 1H), 4.09 (ddd, J = 11.0, 8.0, 5.1 Hz, 1H), 3.28 (ddd,J = 11.6, 7.7, 4.6 Hz, 2H), 2.90 –2.80 (m, 2H), 2.80 – 2.72 (m, 1H), 2.31(ddt, J = 17.3, 7.3, 4.9 Hz, 1H), 2.01 (dtd, J = 17.4,12.3, 2.5 Hz, 2H), 1.90(d, J = 13.8 Hz, 1H), 1.86 – 1.80 (m, 1H), 1.80 – 1.69 (m, 3H), 1.67(dd, J =9.2, 3.5 Hz, 1H), 1.64 – 1.53 (m, 2H), 1.53 – 1.45 (m, 3H); 13C NMR(600 MHz,CDCl3) δ: 163.11,158.08, 157.92, 135.77, 132.44, 131.57, 129.40, 128.71,128.50, 127.85, 126.94, 125.67,124.99, 63.32, 62.68, 57.13, 52.75, 42.91,42.36, 35.52, 27.57, 26.43, 23.36, 22.52, 21.06, 20.73; MS m/z: 432{[M+H]+}
化合物LHW-09:棕色固体粉末,收率32%,m .p.121~128℃; 1H NMR (600 MHz, CDCl3)δ 6.86 (d, J = 20.9 Hz, 1H), 4.31 (d, J = 10.7 Hz, 1H), 3.94 (d, J = 60.3 Hz,1H), 3.12 (d, J = 51.0 Hz, 1H), 2.93 (ddd, J = 21.0, 12.5, 8.4Hz, 1H), 2.83(d, J = 24.8 Hz, 1H), 2.68 – 2.52 (m, 1H), 2.43 –2.37 (m, 3H), 2.24 (d, J =23.7Hz, 2H), 2.00 (s, 1H), 1.89 (d, J = 12.9 Hz, 1H), 1.84 – 1.57 (m, 4H),1.57 – 1.35 (m, 3H); 13CNMR (600 MHz, CDCl3)δ: 167.63, 155.62, 155.41, 139.93,136.38, 128.57, 128.49, 63.30, 57.01, 53.69, 43.33,41.78, 35.20, 28.32,27.47, 26.82, 25.95, 21.18, 20.99, 20.58, 19.91; MS m/z: 424{[M+H]+};
化合物LHW-10:淡黄色固体粉末,收率42%,m .p.121~136℃; 1H NMR (600 MHz,CDCl3) δ 8.09 – 7.84 (m, 2H), 7.39 (d, J = 7.5 Hz, 1H),7.35 (t, J = 7.6 Hz,1H), 4.50 (dd, J = 12.9, 4.5 Hz, 1H), 4.12 –4.05 (m, 1H), 3.36 -3.25 (m,1H),3.02 (t, J = 14.5 Hz, 1H), 2.96 (ddd, J = 17.2, 8.1, 4.7 Hz, 2H), 2.60 (ddd,J = 17.0, 9.6,4.9 Hz, 1H), 2.42 (s, 3H), 2.22 (ddd, J = 13.1, 9.5, 4.9 Hz,1H), 2.06 (dd, J = 24.9, 12.4 Hz,2H), 1.93 (d, J = 14.0 Hz, 1H), 1.90 -1.78(m, 2H), 1.77 -1.68 (m, 3H), 1.67 -1.55 (m, 2H),1.55-1.45 (m, 3H), 1.28 (s,1H); 13C NMR (600 MHz, CDCl3)δ: 171.07, 159.77, 148.79, 138.06, 133.82,130.70,130.44, 128.21, 127.27, 63.60, 56.93, 52.57, 42.71, 41.86, 35.54, 27.44,26.34, 23.02,21.26, 20.81, 20.46, 19.77; MS m/z: 396{[M+H]+};
化合物LHW-11:白色固体粉末,收率51%,m .p.132~136℃; 1H NMR (600 MHz, DMSO)δ 7.56 – 7.51 (m, 1H), 7.44 (dt, J = 8.9, 4.5 Hz,1H), 7.41 (t, J = 7.9 Hz,1H), 7.18 (ddd, J = 8.2, 2.7, 0.8 Hz, 1H), 4.19 (dd, J = 12.5, 4.3 Hz,1H),3.89 – 3.85 (m, 1H), 3.81 (s, 3H), 3.08 (t, J = 12.5 Hz, 1H), 2.80 – 2.69 (m,4H), 2.41(ddd, J = 16.5, 9.6, 4.7 Hz, 1H), 2.06 – 2.01 (m, 1H), 1.91 – 1.83(m, 3H), 1.65 – 1.61 (m,2H), 1.57 (dt, J = 7.6, 3.6 Hz, 2H), 1.56 – 1.50 (m,3H), 1.40 – 1.33 (m, 3H); 13C NMR(600 MHz, DMSO)δ:167.84, 159.72, 159.65,149.68, 130.06, 122.00, 114.37, 63.41, 57.01, 56.94, 55.67, 52.56,42.52,41.55, 40.36, 40.22, 40.08, 39.94, 39.81, 39.67, 39.53, 35.67, 27.80, 26.43,23.21,21.07, 20.61, 19.92; MS m/z: 412{[M+H]+};
化合物LHW-12:白色固体粉末,收率41%,m .p.126~132℃;1H NMR (600 MHz, CDCl3)δ 7.89 (d, J = 7.7 Hz, 1H), 7.77 (t, J = 12.5 Hz, 1H), 7.43 – 7.36(m, 1H),7.26 – 7.21 (m, 1H), 4.49 (dd, J = 13.0, 4.5 Hz, 1H), 4.15 – 4.08 (m, 1H),3.33 (t, J =12.9 Hz, 1H), 3.08 (dd, J = 38.8, 11.0 Hz, 2H), 2.95 (ddd, J =17.1, 8.0, 4.6 Hz, 1H), 2.58(ddd, J = 17.0, 9.7, 4.9 Hz, 1H), 2.21 (ddd, J =13.1, 9.4, 4.8 Hz, 1H), 2.14 – 2.04 (m, 2H),1.93 (d, J = 14.0 Hz, 1H), 1.83(ddd, J = 38.5, 16.6, 8.0 Hz, 2H), 1.78 – 1.66 (m, 3H), 1.66 –1.55 (m, 2H),1.50 (ddd, J = 18.2, 8.2, 3.7 Hz, 3H); 13C NMR δ: 169.61, 159.75, 148.97,129.84, 125.75, 119.79, 116.96, 63.62, 56.83, 52.50,42.59,41.82, 35.45,27.31, 26.21, 23.05,20.65, 20.32, 19.73; MS m/z: 400{[M+H]+};
化合物LHW-13:白色固体粉末,收率48%,m .p.160~167℃;1H NMR (600 MHz, CDCl3)δ 8.02 (t, J = 1.7 Hz, 1H), 7.96 (d, J = 7.8 Hz, 1H), 7.61 – 7.56(m, 1H),7.43 (t, J = 7.9 Hz, 1H), 4.48 (dd, J = 12.8, 4.5 Hz, 1H), 4.11 – 4.00 (m,1H), 3.26 (t, J = 12.8 Hz, 1H), 3.23 – 3.14 (m, 1H), 2.89 – 2.77 (m, 2H),2.73 – 2.63 (m, 1H), 2.28 (ddt, J= 12.2, 7.1, 4.9 Hz, 1H), 2.23 (s, 1H), 2.05– 1.94 (m, 2H), 1.87 (d, J = 13.7 Hz, 1H), 1.84 –1.78 (m, 1H), 1.78 – 1.69(m, 3H), 1.69 – 1.62 (m, 1H), 1.62 – 1.51 (m, 2H), 1.51 – 1.43 (m,3H); 13C NMR(600 MHz, CDCl3)δ: 161.71, 158.34, 157.84, 134.80, 133.66, 130.02, 129.68,127.95, 63.28,57.11, 52.73, 42.89, 42.35, 35.50, 27.56, 26.40, 23.30, 22.52,21.04, 20.70; MS m/z: 416{[M+H]+};
化合物LHW-14: 白色固体粉末,收率35%,m .p.156~165℃;1H NMR (600 MHz, CDCl3)δ 8.18 (t, J = 1.7 Hz, 1H), 8.05 – 7.95 (m, 1H), 7.74 (ddd, J = 8.0,1.9, 1.0Hz, 1H), 7.37 (t, J = 7.9 Hz, 1H), 4.48 (dd, J = 12.8, 4.5 Hz, 1H), 4.11 –4.00 (m, 1H),3.25 (q, J = 12.5 Hz, 1H), 3.22 – 3.15 (m, 1H), 2.90 – 2.76 (m,2H), 2.73 – 2.61 (m, 1H), 2.33– 2.23 (m, 1H), 1.99 (dtd, J = 14.7, 12.3, 2.6Hz, 2H), 1.86 (t, J = 14.5 Hz, 1H), 1.84 – 1.78(m, 1H), 1.78 – 1.69 (m, 3H),1.68 – 1.60 (m, 1H), 1.60 – 1.52 (m, 2H), 1.52 – 1.42 (m, 3H);13C NMR(600 MHz,CDCl3)δ: 161.59, 158.34, 157.83, 136.59, 132.59, 130.25, 128.40, 122.70,63.28, 57.12,52.73, 42.90, 42.36, 35.50, 27.56, 26.41, 23.30, 22.52, 21.04,20.71; MS m/z: 460{[M+H]+};
化合物LHW-15: 淡黄色固体粉末,收率45%,m .p.123~130℃; 1H NMR (600 MHz,DMSO) δ 8.23 (d, J = 7.8 Hz, 1H), 8.18 (s, 1H), 7.99(d, J = 7.8 Hz, 1H), 7.76(t, J = 7.8 Hz, 1H), 4.23 – 4.14 (m, 1H), 3.91 – 3.83 (m, 1H), 3.13 –3.02 (m,1H), 2.83 – 2.75 (m, 2H), 2.73 (ddd, J = 16.5, 8.2, 4.5 Hz, 1H), 2.41 (ddd, J = 16.5,9.6, 4.7 Hz, 1H), 2.06 (qd, J = 9.3, 4.8 Hz, 1H), 2.00 – 1.89 (m, 2H),1.85 (d, J = 13.4 Hz, 1H),1.70 – 1.62 (m, 2H), 1.62 – 1.44 (m, 4H), 1.43 –1.28 (m, 3H); 13C NMR (600 MHz, DMSO)δ: 166.64, 159.72,149.70, 133.66, 130.45,129.88, 129.66, 129.54, 125.96, 125.93, 125.24, 63.42, 56.97, 56.91,42.47,41.48, 35.62, 27.75, 26.38, 23.22, 21.03, 20.57, 19.93; MS m/z: 412{[M+H]+};
化合物LHW-16: 16):白色固体粉末,收率53%,m .p.146~154℃;1H NMR (600 MHz,CDCl3) δ : 7.96 (d, J = 8.2 Hz, 1H), 7.27 (d, J = 8.8 Hz, 1H), 4.49 (dd, J =12.8, 4.5 Hz, 1H), 4.05 (dd, J = 10.9, 8.0, 5.1 Hz, 1H), 3.26 (t,J= 12.8 Hz,1H), 3.18 (dd, J= 16.4, 7.3, 4.3 Hz, 1H), 2.89 ~ 2.77 (m, 1H), 2.71 ~ 2.62(m, 1H), 2.43 (s, 1H), 2.30 ~ 2.21(m, 1H), 1.99 (dd, J = 14.9, 12.3, 2.7 Hz,1H), 1.88 (d, J = 15.2 Hz, 2H), 1.83 ~ 1.77 (m, 1H),1.77 ~ 1.67 (m, 1H), 1.67~ 1.61 (m, 1H), 1.61 ~ 1.51 (m, 1H), 1.51 ~ 1.42 (m, 1H); 13C NMR(600 MHz,CDCl3)δ: 163.98, 158.14, 157.56, 144.53, 129.84, 129.36, 125.70, 63.33,57.12, 56.82, 52.72, 42.89,42.38, 35.52, 27.56, 26.41, 23.36, 22.42, 21.77,21.04, 20.72; MS m/z: 396{[M+H]+};
化合物LHW-17: 白色固体粉末,收率45%,m .p.136~144℃; 1H NMR (600 MHz,CDCl3) δ: 8.19 (d, J = 8.2 Hz, 1H), 7.75 (d, J = 8.3 Hz,1H), 4.48 (dd, J =12.8, 4.5 Hz, 1H), 4.07 (dd, J = 10.9, 8.1, 5.1 Hz, 1H), 3.27 (t, J = 12.8Hz,1H), 3.19 (dd, J = 16.3, 7.2, 4.3 Hz, 1H), 2.89 ~ 2.78 (m, 1H), 2.69 (dd,J = 16.0, 11.0, 4.7 Hz,1H), 2.29 (dd, J = 17.2, 7.2, 4.9 Hz, 1H), 2.02 ~ 1.98(m, 1H), 1.95 (s, 1H), 1.87 (d, J = 13.6Hz, 1H), 1.84 ~ 1.78 (m, 1H), 1.77 ~1.69 (m, 2H), 1.68 ~ 1.61 (m, 1H), 1.60 ~ 1.52 (m, 1H),1.48 (d, J = 6.9, 4.1Hz, 2H); 13C NMR(600 MHz, CDCl3) δ: 161.78, 158.48, 157.78, 131.84, 130.18,125.72,125.69, 63.72, 57.12, 57.11, 52.73, 42.92, 42.39, 35.51, 27.55, 26.41,23.31, 22.52, 21.04, 20.71; MS m/z: 450{[M+H]+};
化合物LHW-18:淡黄色固体粉末,收率49%,m .p.156~162℃; 1H NMR (600 MHz,CDCl3) δ : 8.14 ~ 8.07 (m, 1H), 7.21 ~ 7.13 (m, 1H), 4.50 (dd, J = 12.8,4.5Hz, 1H), 4.12 ~ 4.04 (m, 1H), 3.28 (t, J = 12.8 Hz, 1H), 3.19 (dd, J = 16.4,7.3, 4.3 Hz,1H), 2.85 (dd, J = 31.5, 10.9 Hz, 1H), 2.73 ~ 2.62 (m, 1H), 2.34~ 2.24 (m, 1H), 2.02 (d, J =16.2, 12.0 Hz, 1H), 1.87 (s, 1H), 1.83 (d, J =11.9 Hz, 1H), 1.74 (dd, J = 14.1, 10.2, 4.3 Hz,2H), 1.64 (dd, J = 24.4, 10.1Hz, 1H), 1.61 ~ 1.53 (m, 1H), 1.53 ~1.45(m,2H); 13C NMR(600 MHz, CDCl3)δ:161.99, 157.98, 157.88, 132.44, 132.39, 116.01, 115.87, 63.30, 57.12, 56.89,52.71, 42.92,42.38, 35.52, 27.55, 26.41, 23.31, 22.42, 21.04, 20.71; MS m/z:400{[M+H]+};
化合物LHW-19:白色固体粉末,收率49%,m .p.140~155℃;1H NMR (600 MHz, CDCl3)δ: 8.04 ~ 7.98 (m, 1H), 7.49 ~ 7.43 (m, 1H), 4.49 (dd, J = 12.8,4.5 Hz, 1H),4.07 (s, 1H), 3.28 (t, J = 12.7 Hz, 1H), 3.18 (dd, J = 16.4, 7.3, 4.3 Hz,1H), 2.85(dd, J = 31.8, 10.4 Hz, 1H), 2.74 ~ 2.65 (m, 1H), 2.33 ~ 2.24 (m,1H), 2.04 (s, 1H), 1.88 (d, J= 13.7 Hz, 1H), 1.82 (d, J = 9.5 Hz, 1H), 1.78 ~1.70 (m, 2H), 1.69 ~ 1.62 (m, 1H), 1.57 (dd, J= 18.4, 9.5, 4.2 Hz, 1H), 1.53~ 1.45 (m, 2H);13C NMR(600 MHz, CDCl3) δ: 162.15, 157.97, 157.94, 140.24,131.14, 129.06, 126.90, 63.28, 57.10, 56.88, 52.72, 42.92, 42.35, 35.51,27.54, 26.40, 23.27, 22.42, 21.02, 20.69; MS m/|z: 41{[M+H]+};
化合物LHW-20:淡黄色固体粉末,收率40%,m .p.136~141℃; 1H NMR (600 MHz,CDCl3) δ: 7.93 (d, J = 8.5 Hz, 1H), 7.93 (d, J = 8.5 Hz, 1H), 7.63 (d, J =8.5Hz, 1H), 7.63 (d, J = 8.5 Hz, 1H), 4.49 (d, J = 9.5 Hz, 1H), 4.06 (s, 1H),3.27 (t, J = 12.4Hz, 1H), 3.21 ~ 3.11 (m, 1H), 2.91 ~ 2.74 (m, 1H), 2.73 ~2.56 (m, 1H), 2.25 (t, J = 16.2 Hz,1H), 2.16 (s, 1H), 2.01 (t, J = 18.4 Hz,1H), 1.87 (d, J = 13.1 Hz, 1H), 1.80 (s, 1H), 1.72 (s,3H), 1.64 (d, J = 10.4Hz, 1H), 1.57 (d, J = 8.9 Hz, 1H), 1.48 (s, 2H); 13C NMR(600 MHz, CDCl3) δ:162.21,158.06, 157.92, 132.06, 131.69, 131.23, 128.91, 127.38, 63.31, 57.08,56.77, 52.69, 42.87,42.33, 35.46, 27.51, 26.36, 23.31, 22.44, 20.99, 20.66;MS m/z: 461{[M+H]+};
化合物LHW-21: 淡黄色固体粉末,收率55%,m .p.158~170℃; 1H NMR (600 MHz,CDCl3) δ : 8.03 (t, J = 5.7 Hz, 1H), 6.96 (t, J = 5.7 Hz,1H), 4.49 (dd, J =12.8, 4.5 Hz, 1H), 4.05 (dd, J = 11.0, 8.0, 5.1 Hz, 1H), 3.88 (s, 2H), 3.25(t,J= 12.7 Hz, 1H), 3.18 (dd, J = 16.3, 7.3, 4.3 Hz, 1H), 2.83 (dd, J = 31.6,10.9 Hz, 1H), 2.71 ~2.62 (m, 1H), 2.31 ~ 2.20 (m, 1H), 2.05 ~ 1.93 (m, 1H),1.93 ~ 1.83 (m, 2H), 1.80 (dd, J =17.3, 8.6 Hz, 1H), 1.77 ~ 1.68 (m, 2H),1.68 ~ 1.59 (m, 1H), 1.55 (dd, J = 19.0, 9.9, 4.4 Hz,1H), 1.52 ~ 1.40 (m,2H); 13C NMR(600 MHz, CDCl3) δ: 163.91, 162.63, 158.17, 157.41, 131.93,120.70,113.95, 63.34, 57.14, 57.01, 22.53, 52.71, 42.88, 42.37, 35.53, 27.57,26.43, 23.36, 22.36, 21.06, 20.74; MS m/z: 412{[M+H]+};
化合物LHW-22: 白色固体粉末,收率56%,m .p.122~127℃; 1H NMR (600 MHz,CDCl3) δ 8.02 – 7.98 (m, 1H), 7.52 – 7.47 (m, 1H),4.48 (dd, J = 12.8, 4.5 Hz,1H), 4.10 – 4.01 (m, 1H), 3.31 – 3.22 (m, 1H), 3.21 – 3.13 (m, 1H),2.90 –2.78 (m, 1H), 2.66 (tdd, J = 11.0, 9.1, 4.2 Hz, 1H), 2.29 – 2.23 (m, 1H),2.16 (s, 1H),1.99 (dtd, J = 14.6, 12.2, 2.6 Hz, 1H), 1.87 (d, J = 13.8 Hz,1H), 1.80 (ddd, J = 16.5, 9.1, 2.7Hz, 1H), 1.76 – 1.67 (m, 1H), 1.63 (ddd, J = 21.7, 7.0, 3.5 Hz, 1H), 1.60 – 1.51 (m, 1H), 1.51– 1.43 (m, 1H), 1.36 –1.33 (m, 1H); 13C NMR(600 MHz, CDCl3)δ: 163.03, 158.21, 157.54, 157.41,129.71,125.66, 125.56, 63.31, 57.11, 52.73, 42.92, 42.35, 35.53, 35.21,31.07, 27.55, 26.40, 23.27, 22.31, 21.03, 20.70; MS m/z: 438{[M+H]+};
化合物LHW-23: 23):淡黄色固体粉末,收率56%,m .p.120~135℃; 1H NMR (600 MHz,CDCl3) δ : 8.17 ~ 8.11 (m, 2H), 7.72 ~ 7.68 (m, 2H), 7.66 ~ 7.59 (m,2H), 7.51~ 7.46 (m, 2H), 7.44 ~ 7.38 (m, 1H), 4.50 (dd, J = 12.8, 4.5 Hz, 1H), 4.10 ~4.03 (m,1H), 3.27 (t, J = 12.8 Hz, 1H), 3.22 (dd, J = 16.4, 7.3, 4.3 Hz, 1H),2.84 (dd, J = 32.1, 10.9 Hz,2H), 2.75 ~ 2.64 (m, 1H), 2.32 ~ 2.24 (m, 1H),2.00 (dd, J = 14.9, 12.2, 2.6 Hz, 2H), 1.88 (d,J = 13.6 Hz, 1H), 1.81 (dd, J = 13.5, 10.0 Hz, 1H), 1.64 (dd, J = 15.4, 11.8 Hz, 1H), 1.61 ~1.52 (m, 2H),1.48 (d, J = 13.0, 4.5 Hz, 3H); 13C NMR(600 MHz, CDCl3)δ: 162.77, 158.07,157.91, 142.42,139.80, 130.34, 129.80, 129.01, 128.38, 127.32, 63.35, 57.13,56.95, 52.72, 42.88, 42.62,42.40, 35.52, 27.56, 26.42, 23.41, 22.47, 21.05,20.72; MS m/z: 458{[M+H]+};
化合物LHW-24: 淡黄色固体粉末,收率29%,m .p.152~156℃;1H NMR (600 MHz,DMSO) δ 8.90 – 8.84 (m, 1H), 8.13 (dd, J = 9.6, 3.5 Hz, 1H), 8.00 (d, J= 7.9Hz, 1H), 7.66 – 7.60 (m, 1H), 7.57 (td, J = 7.0, 3.1 Hz, 1H), 4.19 (dd, J =12.5, 4.0 Hz,1H), 3.89 – 3.82 (m, 1H), 3.07 (t, J = 12.6 Hz, 1H), 2.81 – 2.73(m, 1H), 2.72 (ddd, J = 16.7,8.2, 4.7 Hz, 1H), 2.41 (tdd, J = 14.5, 10.0, 4.5Hz, 1H), 2.03 (ddd, J = 34.5, 19.4, 15.2 Hz,1H), 1.96 – 1.86 (m, 1H), 1.81(d, J = 11.2 Hz, 1H), 1.67 – 1.46 (m, 2H), 1.40 – 1.28 (m, 1H);13C NMR(600MHz, DMSO)δ: 169.48, 160.73, 159.74, 149.66, 133.94, 132.97, 131.19, 130.02,129.00, 127.81,126.54, 126.14, 125.35, 63.34, 56.91, 52.51, 42.46, 41.48,40.38, 39.54, 35.60, 27.72, 26.33, 23.21, 21.00, 20.54, 19.93. MS m/z: 432{[M+H]+};
通过本发明制备的上述苦参碱肟酯类衍生物,其构成纯度在99%以上。
以下表1给出了制备目标化合物的结构式:
本发明还包括,所述苦参碱衍生物在制备抗肿瘤药物中的应用。优选的,所述肿瘤为肝癌、肺癌、胃癌细和乳腺细。
以下通过实验进一步说明本发明的有益效果。
药理实验:
人类肝癌细胞(Bel-7402)和人类乳腺癌细胞(MCF-7)培养在%胎牛血清和1%青霉素-链霉素的RPMI1640培养基中;人类胃癌细胞(SGC-7901)培养在含10%FBS和1%青霉素的DMEM高糖培养基中;人类肺癌细胞(H460) 培养在含10%FBS和1%青霉素-链霉素的McCoy5A培养基中;所有细胞都置于37℃,5%CO2的细胞培养箱中。
用MTT法进行测试,将苦参碱、苦参碱肟酯类化合物溶解后用基础培养基稀释成母液。取0.5x106 个对数生长期的以上细胞株,接种于96 孔板中,每孔100μL(5000 个细胞),设空白组、对照组以及给药组(50μM),每组设4个平行孔。置于37℃、5%(V/V)CO2的培养箱中,24h 后加入同一浓度的药物,继续培养72h,终止前除去上清,每空加入30μL 5 mg/mLMTT,培养箱孵育4h 后除去MTT并加入100μL DMSO/孔,置摇床上低速振荡10min,使结晶物充分溶解,运用酶标仪在490nm 波长处测定各孔吸光度(OD)值,计算细胞增殖抑制率,细胞增殖抑制率=(1-样品OD值/对照组OD值)×100%。
上述实验重复3 次,并用Blies法计算出IC50 值,组间进行比较采用的是t 检验法,P < 0.05 为差异有显著性。
实验结果:
表2目标化合物对Bel-7402,SGC-7901,MCF-7和H460细胞增殖的抑制
药理实验结果表明:合成的系列苦参碱衍生物均有抗肿瘤活性作用,在以苦参碱为对照药,与合成的LHW系列化合物同时给药的情况下,通过对比它们的抑制率发现,所有的化合物的活性均优于对照药苦参碱,LHW-03、LHW-08、LHW-11、LHW-13、LHW-16、LHW-17、LHW-18、LHW-19、LHW-22、LHW-23均小于50µM,其中LHW-03、LHW-17、LHW-22均小于10µM,活性有了明显的提高。
本发明在于提供了一种有望成为高效低毒的抗肿瘤药物,给广大癌症患者多一种治疗的选择。
本发明还包括,所述苦参碱衍生物在杀虫药物中的应用。优选的,所述害虫为红蜘(Panonychus citri),健康、活泼、大小一致的3 龄幼虫,由广西田园生化股份有限公司生测室提供。蚜虫(Aphidoidea),健康、活泼、大小一致的若虫,由广西田园生化股份有限公司生测室提供。
以下通过实验进一步说明本发明的有益效果。
药理实验:
1、红蜘蛛触杀活性试验:
采用叶片浸渍法,将所合成的苦参碱肟酯类化合物以二甲基亚砜(DMSO)和10%吐温80(93.5%)配成母液,用水稀释到200 ppm的药液,将无污染的新鲜酢浆草逐一在配好的稀释液中浸渍5s,拿出置吸水纸上晾干,然后接入试虫,任其取食带药叶片,以含有二甲基亚砜的10%吐温80(93.5%)水溶液作为空白对照,盒盖后置于室温的环境下,48h检查结果。死亡标准:以毛笔尖触其虫体, 无任何反应者为死亡。死亡率和有效率分别用公式1-1和公式1-2计算。校正死亡率和校正有效率使用Abbott公式进行校正。
公式1-1:
公式1-2:
2、蚜虫触杀活性试验:
同样采用叶片浸渍法,将所合成的苦参碱肟酯类化合物以二甲基亚砜(DMSO)和10%吐温80(93.5%)配成母液,用水稀释到200 ppm的药液,将无污染的新鲜小豆苗逐一在配好的稀释液中浸渍5s,拿出置吸水纸上晾干,然后接入试虫,任其取食带药叶片,以含有二甲基亚砜的10%吐温80(93.5%)水溶液作为空白对照,盒盖后置于室温的环境下,48h检查结果。死亡标准:以毛笔尖触其虫体, 无任何反应者为死亡。死亡率和有效率分别用公式1-1和公式1-2计算。校正死亡率和校正有效率使用Abbott公式进行校正。
实验结果:
本实验选取了两种田间常见害虫—红蜘蛛和蚜虫为实验对象,采用叶片浸渍法测试苦参碱肟酯类衍生物对害虫的触杀活性(死亡率),结果如表3所示。
表3. 目标化合物对害虫的触杀活性
编号 | 对红蜘蛛触杀活性 | 对蚜虫触杀活性 | 编号 | 对红蜘蛛触杀活性 | 对蚜虫触杀活性 |
LHW-01 | - | - | LHW-13 | 0.36 | 0.30 |
LHW-02 | 0.55 | 0.61 | LHW-14 | 0.53 | 0.61 |
LHW-03 | 0.67 | 0.96 | LHW-15 | 0.85 | 0.91 |
LHW-04 | 0.10 | 0.93 | LHW-16 | 0.93 | 0.80 |
LHW-05 | 0.10 | 0.95 | LHW-17 | 0.97 | 0.99 |
LHW-06 | 0.99 | 0.94 | LHW-18 | 0.96 | 0.94 |
LHW-07 | 0.88 | 0.93 | LHW-19 | 0.96 | 0.84 |
LHW-08 | 0.97 | 0.74 | LHW-20 | 0.14 | 0.52 |
LHW-09 | 0.93 | 0.95 | LHW-21 | 0.98 | 0.13 |
LHW-10 | 0.84 | 0.81 | LHW-22 | 0.00 | 0.12 |
LHW-11 | 0.97 | 0.22 | LHW-23 | 0.96 | 0.08 |
LHW-12 | 0.08 | 0.70 | LHW-24 | 0.00 | 0.82 |
阿维菌素 | 1.00 | 0.99 | 苦参碱 | 0.21 | 0.48 |
药理实验结果表明:合成的系列苦参碱衍生物均有抗肿瘤活性作用,在以苦参碱和阿维菌素为对照药,与合成的LHW系列化合物同时给药的情况下,通过对比它们的杀虫死亡率发现,在给药浓度为200 ppm时,较苦参碱而言,对红蜘蛛具有较好的触杀活性。其中有10个目标化合物活性达到了90%以上,9个化合物与对照组阿维菌素的触杀活性接近,LHW-06的活性达到了99%。在目标化合物对蚜虫的触杀活性测试中,其中有9个目标化合物活性达到了90%以上,化合物与对照组阿维菌素的触杀活性接近,其中LHW-17的活性达到了99%。
本发明在于提供了一种有望成为高效低毒无污染的杀虫药物,给广大农民多一种治疗的选择。
Claims (4)
1.一种苦参碱衍生物,其特征在于所述化合物具有以下结构:
。
2.根据权利要求1所述的苦参碱肟衍生物LHW-01的制备方法,其特征在于以苦参碱为起始原料,经过强碱双(三甲基硅基)氨基钠使苦参碱内酰胺键α位上的氢离去,形成α—碳负离子,然后再与亚硝酸叔丁酯反应即得。
3.根据权利要求1所述的肟酯类苦参碱衍生物LHW-02~LHW-24的制备方法,其特征在于以LHW-01苦参碱肟为起始原料,吡啶作为缚酸剂,然后加入苯甲酰氯类化合物进行成酯反应,反应即得苦参碱肟酯衍生物。
4.根据权利要求1所述的苦参碱肟和苦参碱肟酯衍生物在制备杀虫和抗癌药物的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610493154.8A CN106146497A (zh) | 2016-06-29 | 2016-06-29 | 苦参碱肟酯衍生物及其制备方法与应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610493154.8A CN106146497A (zh) | 2016-06-29 | 2016-06-29 | 苦参碱肟酯衍生物及其制备方法与应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN106146497A true CN106146497A (zh) | 2016-11-23 |
Family
ID=57350412
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610493154.8A Pending CN106146497A (zh) | 2016-06-29 | 2016-06-29 | 苦参碱肟酯衍生物及其制备方法与应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN106146497A (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111153904A (zh) * | 2020-01-14 | 2020-05-15 | 广西大学 | 一种苦参碱肟酯和肟醚衍生物及其制备方法和应用 |
CN114621226A (zh) * | 2022-04-21 | 2022-06-14 | 广西大学 | 一种苦参碱衍生物及其制备方法和应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101863887A (zh) * | 2010-06-01 | 2010-10-20 | 广西大学 | 苦参碱衍生物及其制备方法 |
CN102786522A (zh) * | 2012-07-17 | 2012-11-21 | 广西大学 | 苦参碱衍生物及其制备方法和应用 |
CN104926814A (zh) * | 2015-06-14 | 2015-09-23 | 广西大学 | 苦参碱衍生物及其应用 |
CN105294490A (zh) * | 2015-09-10 | 2016-02-03 | 江苏长青农化股份有限公司 | 一种合成肟菌酯的方法 |
-
2016
- 2016-06-29 CN CN201610493154.8A patent/CN106146497A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101863887A (zh) * | 2010-06-01 | 2010-10-20 | 广西大学 | 苦参碱衍生物及其制备方法 |
CN102786522A (zh) * | 2012-07-17 | 2012-11-21 | 广西大学 | 苦参碱衍生物及其制备方法和应用 |
CN104926814A (zh) * | 2015-06-14 | 2015-09-23 | 广西大学 | 苦参碱衍生物及其应用 |
CN105294490A (zh) * | 2015-09-10 | 2016-02-03 | 江苏长青农化股份有限公司 | 一种合成肟菌酯的方法 |
Non-Patent Citations (2)
Title |
---|
宋宝安等: "肟类衍生物的合成与农药生物活性的研究进展", 《有机化学》 * |
罗金香等: "姜黄素双肟酯衍生物的合成与生物活性研究", 《西南大学学报(自然科学版)》 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111153904A (zh) * | 2020-01-14 | 2020-05-15 | 广西大学 | 一种苦参碱肟酯和肟醚衍生物及其制备方法和应用 |
CN114621226A (zh) * | 2022-04-21 | 2022-06-14 | 广西大学 | 一种苦参碱衍生物及其制备方法和应用 |
CN114621226B (zh) * | 2022-04-21 | 2023-06-06 | 广西大学 | 一种苦参碱衍生物及其制备方法和应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103946231B (zh) | 齐墩果酸酰胺化衍生物、及其制备方法和应用 | |
CN108727460B (zh) | 白桦脂酮酸衍生物及其合成方法和应用 | |
CN108503681B (zh) | 白桦脂酸衍生物及其合成方法和应用 | |
CN106146497A (zh) | 苦参碱肟酯衍生物及其制备方法与应用 | |
CN107709335B (zh) | Kakeromycin及其衍生物的制造方法 | |
CN104761482A (zh) | 3-(2,2-二甲基)丙氰基-3-烷(芳)基吲哚酮及其制备方法 | |
CN108912108B (zh) | 三氟甲基化合物及其制备方法及其在农药中的应用 | |
CN104586842B (zh) | 一种抗癌活性吲哚衍生物、合成方法及其用途 | |
CN103435560B (zh) | 一类带柔性侧链的苊并[1,2-b]喹喔啉衍生物的合成及其应用 | |
CN103864765B (zh) | 含有五元杂环的苯并氮杂卓类衍生物、其制备方法和用途 | |
CN102276433B (zh) | 木豆素c及其衍生物及其在制备抗癌药物中的应用 | |
CN112979672B (zh) | 11,20-二羰基冬凌草甲素14-o酯化系列衍生物及其用途 | |
CN107253949A (zh) | 一类硫杂吴茱萸次碱化合物及其在抗肿瘤药物中的应用 | |
CN106220642A (zh) | 一种l‑亮氨酸取代去甲斑蝥素衍生物及其制备方法与应用 | |
CN106083884A (zh) | 一种d‑亮氨酸取代去甲斑蝥素衍生物及其制备方法与应用 | |
CN106188080A (zh) | 一种d‑苯丙氨酸取代去甲斑蝥素衍生物及其制备方法与应用 | |
CN105732758B (zh) | 胆酸‑α‑氨基膦酸酯衍生物及其合成方法 | |
CN106083873A (zh) | 一种l‑苯丙氨酸取代去甲斑蝥素衍生物及其制备方法与应用 | |
CN104039794B (zh) | 7‑位取代的汉防己乙素衍生物、及其制备方法和应用 | |
CN106748973A (zh) | 两种叠氮化药物及其制备方法和应用 | |
CN109206389A (zh) | 异土木香内酯衍生物,其药物组合物及其用途 | |
CN102336764B (zh) | 自旋标记鱼藤酮肟酯及其制备方法和用途 | |
CN106188081A (zh) | 一种d‑缬氨酸取代去甲斑蝥素衍生物及其制备方法与应用 | |
CN104961794B (zh) | 一种丹参酮iia衍生物及其制备和应用 | |
CN107722029B (zh) | 一种含哒嗪酮结构的d-亮氨酸取代去甲斑蝥素衍生物的制备方法及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20161123 |
|
WD01 | Invention patent application deemed withdrawn after publication |